Mutation and drug-specific intracellular accumulation of EGFR predict clinical responses to tyrosine kinase inhibitors

BACKGROUND: Clinical responses to EGFR tyrosine kinase inhibitors (TKIs) are restricted to tumors harboring specific activating mutations and even then, not all tyrosine kinase inhibitors provide clinical benefit. All TKIs however, effectively inhibit EGFR phosphorylation regardless of the mutation...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:EBioMedicine
Main Authors: de Wit, Maurice, Gao, Ya, Mercieca, Darlene, de Heer, Iris, Valkenburg, Bart, van Royen, Martin E., Aerts, Joachim, Sillevis Smitt, Peter, French, Pim
Formato: Artigo
Idioma:Inglês
Publicado em: Elsevier 2020
Assuntos:
Research paper
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7276512/
https://ncbi.nlm.nih.gov/pubmed/32512509
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.ebiom.2020.102796
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados